glp 1 agonist black box warning What are experts learning about the long-term effects of GLP-1 medications? As more people stay on these medications for longer periods of time, researchers are paying closer attention to potential side effects I'm Worried! Triple Agonist GLP-1

Jama 323 , 11751183 (2020)

Wegovy holds broader pediatric approval, while Zepbound offers OSA-specific indications

As seen below, the change in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS), reflecting physical limitations and symptoms, nearly doubled

Mass tort pharmaceutical cases typically take 3 to 7 years from initial filing to final resolution

According to NICE guideline NG28, GLP-1 receptor agonists should be considered when: Triple therapy (metformin and two other oral drugs) is not effective, not tolerated, or contraindicated The patient has a BMI 35 kg/m (or lower in people of Black, Asian and other minority ethnic groups) and specific obesity-related comorbidities The patient has a BMI 40% reduction in non-HDL cholesterol GLP-1 receptor agonist for glycaemic control and weight management (with secondary lipid benefits) Ezetimibe if non-HDL cholesterol reduction is insufficient Lifestyle interventions addressing diet, exercise, and weight Monitoring and follow-up are essential components of cholesterol management